secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2025-09-22T23:59:59+00:00
Accession:  0001193125-25-209934
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent completes NDA submission to FDA for zidesamtinib in ROS1-positive NSCLC
--------------------------------------------------------------------------------

- Completed NDA submission to FDA for zidesamtinib.
- Indication: TKI pre-treated advanced ROS1-positive non-small cell lung cancer.
- Submission date: September 22, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000119312525209934/0001193125-25-209934-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000119312525209934/nuvl-20250922.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-209934

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer